Dianthus Therapeutics, Inc
Price
OptionsOpen the Sheet →FilingsNewest: 13G, Stake over 5%, passiveAug 13 →InsidersNo open-market buys. 6 insiders sold $41.9M, all 33 sales on a 10b5-1 plan.→HoldersFMR 15.0%BlackRock 7.5%Wellington Management Group LLP 5.9%→PeersClosest companies: SYRE, APGE, VRDN→
From the filings
Figures
- Revenue
- $2.0Mlast 12 months
- Net income
- −$192.2Mlast 12 months
- Operating cash flow
- −$130.3Mlast 12 months
- Cash and equivalents
- $110.5Mat the last balance sheet
- Shares outstanding
- 54.8M shareson issue